摘要
目的探讨腹膜透析联合血液透析改善终末期肾病患者心肾功能、腹膜功能、营养状况及减少并发症的效果。方法采用回顾性分析,选取丽水市中心医院和丽水市人民医院2019年1月至2022年5月收治的终末期肾脏病患者90例为观察对象,根据治疗方法分为对照组、观察组,每组45例。对照组接受腹膜透析治疗,观察组接受腹膜透析联合血液透析治疗。观察两组心肾功能、腹膜功能、营养状态的变化及并发症发生情况。结果治疗后,观察组心胸比[(57.02±3.35)%]、脑钠肽[(8849.34±124.65)ng/L]、左室质量指数[(181.32±8.56)g/m^(2)]、尿素氮[(14.04±1.94)mmol/L]、血肌酐[(181.47±27.06)μmol/L]均显著低于对照组[(58.92±3.11)%、(15126.39±322.82)ng/L、(187.28±8.95)g/m^(2)、(18.49±2.82)mmol/L、(196.56±31.07)μmol/L](t=2.79、121.68、3.23、8.72、2.46,均P<0.05);观察组射血分数[(63.47±5.23)%]、白蛋白[(52.98±6.37)g/L]、血红蛋白[(114.94±13.61)g/L]均显著高于对照组[(60.46±5.18)%、(47.01±6.04)g/L和(98.04±10.93)g/L](t=-2.74、-4.52、-6.49,均P<0.05);观察组透析液/血浆肌酐比(0.56±0.09),β2微球蛋白[(18032.29±718.11)mg/L]均显著低于对照组[(0.61±0.07)和(18424.42±736.43)mg/L](t=2.54、2.06,P<0.05)。观察组并发症发生率[11.11%(5/45)]显著低于对照组[31.11%(14/45)](χ^(2)=4.27,P<0.05)。结论腹膜透析联合血液透析可改善终末期肾病患者心肾功能、腹膜功能和营养状况,降低并发症发生率,值得推广。该研究成果具备显著创新性和科学性。
Objective To investigate the effects of peritoneal dialysis combined with hemodialysis on improving cardiac and renal function,peritoneal function,and nutritional status,and reducing complications in patients with end-stage renal disease.Methods A total of 90 patients with end-stage renal disease who received treatment at Lishui Municipal Central Hospital and Lishui People's Hospital from January 2019 to May 2022 were retrospectively included in this study.The patients were divided into a control group and an observation group,with 45 patients in each group,based on the treatment methods used.The control group received peritoneal dialysis treatment,while the observation group received a combination of peritoneal dialysis and hemodialysis treatment.The changes in cardiac and renal function,peritoneal function,nutritional status,and the occurrence of complications were observed in both groups.Results After treatment,the observation group showed significantly lower values in the cardiothoracic ratio[(57.02±3.35)%],brain natriuretic peptide[(8849.34±124.65)ng/L],left ventricular mass index[(181.32±8.56)g/m^(2)],blood urea nitrogen[(14.04±1.94)mmol/L],and serum creatinine[(181.47±27.06)μmol/L]compared with the control group[(58.92±3.11)%,(15126.39±322.82)ng/L,(187.28±8.95)g/m^(2),(18.49±2.82)mmol/L,(196.56±31.07)μmol/L,t=2.79,121.68,3.23,8.72,2.46,all P<0.05].Additionally,the observation group had significantly higher levels of ejection fraction[(63.47±5.23)%],albumin[(52.98±6.37)g/L],and hemoglobin[(114.94±13.61)g/L]compared with the control group[(60.46±5.18)%,(47.01±6.04)g/L,(98.04±10.93)g/L,t=-2.74,-4.52,-6.49,all P<0.05].The observation group also exhibited a significantly lower dialysate/plasma creatinine ratio[(0.56±0.09)]and a lower level ofβ2-microglobulin[(18032.29±718.11)mg/L]compared with the control group[(0.61±0.07),(18424.42±736.43)mg/L,t=2.54,2.06,both P<0.05].The incidence of complications in the observation group was 11.11%(5/45),which was significantly lower than that in the c
作者
张旭珍
张彬娥
毛明锋
周飞燕
Zhang Xuzhen;Zhang Bin'e;Mao Mingfeng;Zhou Feiyan(Blood Purification Center,Lishui Municipal Central Hospital,Lishui 323000,Zhejiang Province,China;Department of Nephrology,Lishui Municipal Central Hospital,Lishui 323000,Zhejiang Province,China;Department of Nephrology,Lishui People's Hospital,Lishui 323000,Zhejiang Province,China)
出处
《中国基层医药》
CAS
2024年第11期1661-1665,共5页
Chinese Journal of Primary Medicine and Pharmacy
基金
浙江省丽水市公益性技术应用研究计划(2019SJZC41)。
关键词
腹膜透析
血液透析滤过
肾功能衰竭
慢性
肾功能试验
利钠肽
脑
血清白蛋白
Β2微球蛋白
Peritoneal dialysis
Hemodiafiltration
Kidney failure,chronic
Kidney function tests
Natriuretic peptide,brain
Serum albumin
Beta 2-microglobulin
